SciHub
文献互助
期刊查询
一搜即达
科研导航
交流社区
登录
注册
发布
文献
求助
首页
我的求助
捐赠本站
亲爱的研友该休息了!由于当前在线用户较少,发布求助请尽量完整的填写文献信息,科研通机器人24小时在线,伴您度过漫漫科研夜!身体可是革命的本钱,早点休息,好梦!
thinker4610
Lv1
50 积分
2021-07-20 加入
最近求助
最近应助
互助留言
Discovery and preclinical evaluations of TQB3616, a novel CDK4-biased inhibitor
12天前
已完结
Discovery and preclinical evaluations of TQB3616, a novel CDK4-biased inhibitor
12天前
已关闭
Updated results of a phase 1b/2 study of surufatinib plus camrelizumab, nab-paclitaxel and S-1 (NASCA) as first-line therapy for metastatic pancreatic adenocarcinoma (mPDAC)
4个月前
已完结
Efficacy and safety of a targeted-release formulation of budesonide in patients with primary IgA nephropathy (NefIgArd): 2-year results from a randomised phase 3 trial
4个月前
已完结
Efficacy and safety of dupilumab in patients with severe chronic rhinosinusitis with nasal polyps (LIBERTY NP SINUS-24 and LIBERTY NP SINUS-52): results from two multicentre, randomised, double-blind, placebo-controlled, parallel-group phase 3 trials
5个月前
已完结
Bispecific antibodies
10个月前
已完结
Bispecific antibodies in oncology
10个月前
已完结
Antibody-Drug Conjugates in Lung Cancer: Recent Advances and Implementing Strategies
1年前
已完结
Challenges and opportunities in the PD1/PDL1 inhibitor clinical trial landscape
1年前
已完结
Sintilimab plus chemotherapy for patients with EGFR-mutated non-squamous non-small-cell lung cancer with disease progression after EGFR tyrosine-kinase inhibitor therapy (ORIENT-31): second interim analysis from a double-blind, randomised, placebo-controlled, phase 3 trial
1年前
已完结
没有进行任何应助
信息填错【积分已退回】
12天前
文献已经正式发表 需要正式版文献
12天前
帮大忙了
4个月前
速度真快
1年前
速度真快
2年前
最近帖子
最近评论
没有发布任何帖子
没有发布任何评论